expanded NK cells

PreclinicalCell therapy

PPeking University People's Hospital

expanded NK cells is one of 20 biologic programs targeting Transplantation. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

TransplantationUnknown status

TransplantationPreclinical

Unknown status

Competition

Competitive Landscape

23 competitors in Transplantation

#DrugCompanyPhaseTrials

Rituxan

Roche

Phase 3

5 2

Atgam

Novartis

Phase 3

5 3

Olumiant

Eli Lilly

Phase 3

1 4

Fludara

Sanofi

Phase 2

14 5

Neupogen

EEastern Cooperative Oncology Group

Phase 3

3 6

Trexall

Jazz Pharmaceuticals

Phase 2

3 7

Cytoxan

BBaxter Healthcare Corporation

Phase 2

13 8

Alkeran

AApotex Inc.

Phase 2

13 9

Actemra

Roche

Phase 2

1 10

Keppra

UCB

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Transplantation1 trial

CMV Infection and Immune Intervention After Transplantation

Unknown status·PPeking University People's Hospital·N/A·NCT04320303·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for expanded NK cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — expanded NK cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for expanded NK cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Peking University People's Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Preclinical[1]
Company: PPeking University People's Hospital

expanded NK cells

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Transplantation1 trial

References

Drug Info

Quick Facts

Related News